Pérez Granda, María JesúsMuñoz García, Patricia CarmenGarcía Martínez, RitaVillalba García, María VictoriaPuente Maestu, LuisBouza Santiago, Emilio2025-01-232025-01-232023-02-01Pérez-Granda MJ, Catalán P, Muñoz P, Aldámiz T, Barrios JC, Ramírez C, García-Martínez R, Villalba MV, Puente L, Bouza E. Cytomegalovirus reactivation in patients diagnosed with severe COVID-19: A point prevalence study in a general hospital. Rev Esp Quimioter. 2023 Feb;36(1):45-51. doi: 10.37201/req/068.2022. Epub 2022 Nov 22. PMID: 36408974; PMCID: PMC9910675.0214-342910.37201/req/068.2022https://hdl.handle.net/20.500.14352/115708Fondos FEDERPurpose To determine the prevalence of CMV reactivation in a population admitted for severe COVID-19 to a general hospital. Methods Point prevalence study in all hospitalized patients with severe COVID-19 (admitted either to general wards or ICU). Determination of the presence of CMV DNA in circulating blood. COVID-19 was confirmed in patients with compatible clinical manifestations, usually with pneumonia and a positive nasopharyngeal PCR test. Results We included 140 hospitalized patients with COVID-19 who consented to participate. A total of 16 patients (11.42%), had circulating CMV-DNA in peripheral blood at the time of the study. Patients with positive CMV viral load were mainly ICU patients (11/37 -29,7%) and only 5/103 cases (4,85%) were hospitalized into general wards. The accumulated doses of corticosteroids (prednisone equivalents) in the study day were (median and IQR) 987.50 mg (396.87-2,454.68) and 187.50 mg (75.00-818.12) respectively in CMV positive and negative patients (p < 0.001). A significant proportion of CMV positive patients were discovered because of the study and were clinically unsuspected by their physicians. The coin-fected COVID-CMV positive population had a higher risk of accumulated secondary nosocomially-acquired infections and a worse prognosis. Conclusion CMV reactivation should be systematically searched in patients in COVID-19 cases admitted to the ICU.engAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/journal article1988-9518http://www.doi.org/10.37201/req/068.202236408974https://seq.es/abstract/rev-esp-quimioter-2022-november-22-2/https://pubmed.ncbi.nlm.nih.gov/36408974/open access616.98:578.834579CytomegalovirusCOVID-19HumanNosocomial infectionCoinfectionEnfermedades infecciosas2414 Microbiología